Arrhythmias and An Update





The Division of Cardiovascular Medicine

The Office of Continuing Medical Education

present

2011

An Update on Therapy: Heart Failure, Hypertension, Arrhythmias, and Valvular Disease

> Saturday, **JANUARY 29, 2011**

> > **Program Director URI ELKAYAM. MD**

MILLENNIUM BILTMORE HOTEL DOWNTOWN, LOS ANGELES, CALIFORNIA







Officially endorsed by the Heart Failure Society of America.

Needs Assessment

Heart Failure (HF) involves about 5 million Americans and is a major cause of morbidity and mortality and decompensated HF due to myocardial and valvular heart disease is the number one cause of hospitalizations in the US in the elderly. Hypertension and metabolic syndrome are important risk factors for the development of HF and early treatment of prehypertension has been recommended but not implemented (Winegarden CR. Am Epidemiol 2005:15; 720). Erectile dysfunction is common in patients with HF, many of them however, are not diagnosed and not appropriately treated (Schwarz ER et al. JACC 2006; 48:1111). Pulmonary hypertension is a major cause of right ventricular failure and has been an increasing cause of death in the US. Recent information suggests the need for more education regarding diagnosis and management (Galie N et al Eur Heart J 2009; 30:2493) and in addition the need for recent guidelines to be adopted by practicing physicians has been emphasized (Badesch DB et al. Chest 2007; 131:1917). Sleep apnea is an important cause of HF but many patients are not diagnosed or treated (Goffleib DJ. Circulation 2010; 122:352). Recent introduction of biomarkers for the diagnosis of HF has provided an important tool for the clinicians. There is however a need for education regarding a cost effective use of these diagnostic tools (Steinhart et al JACC 2009; 54:1515). Since arrhythmias have been shown to unfavorably affect symptoms and lead to worsening of HF and to sudden death, effective therapy for prevention and treatment is the key. Furthermore there is a need to identify effective methods to increase the adoption of proven therapies and close the existing gap between knowledge and practice in the treatment of both atrial and ventricular arrhythmias (Zipes et al Circulation 2006; 114:1088). Recent data have shown that drugs and devices that have been proven beneficial and are recommended in recent practice guidelines (HFSA 2010 update of practice guidelines Lindelfeld J et al J Cardiac Failure 2010:16; 475) are underutilized (Fonarow GC et al. Circulation 2010: 122: 585). The importance of correcting these deficiencies in knowledge and practice is evidenced from the results of recent studies which have demonstrated that increased use of evidence based, life sustaining therapies and performance measures have a significant impact on the outcome of patients with HF (OPTIMIZE-HF, JAMA 2007; 297: 61). New developments in the treatment of HF, due to valvular heart disease, provide an opportunity to improve outcome for patients. Physician update is needed in order to enhance knowledge and an understanding of how to select the appropriate therapy for the individual patient (Bonow et al. Circulation 2008; 98:1949). Recent information suggests a significant individual variability in conformity to quality-of-care indicators and clinical outcome of patients with HF and a substantial gap in overall performance. Establishing educational initiatives such as this program, are aimed to reduce practice variability, eliminate this gap and improve the care of patients with HF (Fonarow GF et al Arch

Desirable Physician Attributes

In alignment with the CME mission of the Keck School of Medicine, programs are planned in the context of desirable physician attributes and core competencies (six abilities that are central to the practice of medicine): 1) Patient Care or Patient-Centered Care, 2) Medical Knowledge, 3) Practice-Based Learning, 4) Interpersonal and Communication Skills, 5) Professionalism, 6) Systems- Based Practice, 7) Interdisciplinary Teams, 8) Quality Improvement, 9) Utilize Informatics, and 10) Employ Evidence-Based Practice, as designated by the American Board of Medical Specialties and the ACGME. Core competencies addressed in each of the activity objectives will be noted, using numbers 1-10, on this brochure and in the proceedings. This shall serve the best interests of the public and assist attendees in Maintenance of Certification.

Accreditation

The Keck School of Medicine of the University of Southern California is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for

The Keck School of Medicine of the University of Southern California designates this live activity for a maximum of 7AMA PRA Category 1 credits ™. Physicians should only claim credits commensurate with the extent of their participation in the activity.

The California State Board of Pharmacy accepts as continuing professional education those courses that meet the standard of relevance to pharmacy practice and have been approved by the AMA for Category 1 credit. Pharmacists licensed in States other than California should inquire with those State Boards for specific continuing education policies.

The California Board of Registered Nursing accepts courses approved for Category 1 credit as meeting the continuing education requirements for license renewal.

Program Description

This course has been designed to educate cardiologists, internists, primary care physicians, pharmacists and other healthcare providers by presenting evidence-based information, published guidelines and the current standard of care enabling them to improve their competency and efficiency in the prevention and treatment of heart failure.

Program Objectives

The goal of the program is to provide cardiologists, internists, primary care providers, pharmacists and other healthcare providers with the necessary information to increase knowledge and improve performance through the accomplishment of the following objectives. At the end of this program, the participants will be able to:

- Select the appropriate therapy for the high risk patient with hypertension.
- Manage heart failure and arrhythmias more effectively.
- Incorporate the use of biomarkers in the diagnosis of heart failure.
- Apply information obtained from recent studies and guidelines to work toward prevention of heart failure and sudden death in high risk patients.
- Implement recent guidelines for the use of drugs and devices in the management of heart failure, hypertension, arrhythmias and valvular heart disease.
- Incorporate new and emergent therapies for hypertension and heart failure related arrhythmias and valvular heart disease.

The program and objectives have been developed in the context of attributes 1, 2, 3, 5 & 10.

Acknowledgments

We gratefully acknowledge the following companies for providing educational grants to support this meeting:

Otsuka America Pharmaceutical, Inc.

St. Jude Medical, Inc. Medtronic, Inc. Ortho-McNeil Janssen Scientific Affairs,

> **Bristol Myers Squibb** Actelion Pharmaceuticals US, Inc. **Thoratec Corporation Gilead Sciences**

> > **Exhibitors:** Cardiac Assist. Inc.

Dugaram

<i>Prog</i>	gram ————————————————————————————————————		
7:00a	Registration and Coffee	1:00p	Vasopressin Receptor
7:50	Opening Remarks		Antagonists: How and When To
	Uri Elkayam, MD		Use Therm?
8:00	The Approach to Prehypertension		Clyde W. Yancy, MD
	and Hypertension in Patients	1:20	Antiplatelets and Anticoagulation
	with the Cardiometabolic		for Prevention of
	Syndrome and Diabetes Mellitus		Thromboembolism in Patients
	Vito M. Campese, MD		with Heart Failure
8:20	Erectile Dysfunction in Heart		Tien M.H. Ng, PharmD
	Failure Patients	1:40	Palliative Care for Patients with
	Ernst R. von Schwarz, MD, PhD		End Stage Heart Failure
8:40	Pulmonary Hypertension: Focus		Pamelyn Close, MD, MPH
	on the Mildly Symptomatic	2:00	Pitfalls in the Selection of
	Patient, Who Should be Treated		Patients for Cardiac
	and How?		Resynchronization Therapy
	Richard N. Channick, MD		Jonathan S. Steinberg, MD
9: <mark>00</mark>	Patient Evaluation and Effective	2:20	Trouble Sho <mark>ot</mark> ing Pacemakers
	Treatment of Sleep Appnea in		and Implantable Cardioverter,
	Patients with Heart Failure		Defibrillators Desid Consider MD Disp
0.00	Douglas L. Prisco, MD	0.40	David Cesario, MD, PhD
9:20	Use of Ultrafiltration in the Management of Decompensated	2:40 3:00	Break & Exhibits New Generation Left Ventricular
	Heart Failure: When and	3.00	Assist Devices for Bridge to
	How to Do It?		Transplantation and Destination
	Andrew J. Burger, MD		Therapy: Patient Selection and
9:40	Break & Exhibits		Outcome
10:00	A Practical Approach for the Use		Andrew J. Boyle, MD
	of Biomarkers in Heart Failure	3:20	End Stage Heart Failure: Heart
	Alan Maisel, MD		Transplantation, Left Ventricular
10:20	Hypertrophic Cardiomyopathy:		Assist Device or Both?
	Risk Evaluation and Strategies		Michael E. Bowdish, MD
	for Prevention of Sudden Death	3:40	Current Status of Transcatheter
	Barry J. Maron, MD		Aortic Valve Implantation
10:40	Atrial Fibrillation: Is Rate Control		Raj Makkar, MD
	Really Equal to Rhythm Control?	4:00	Percutaneous Mitral Valve
	Jonathan S. Steinberg, MD		Repair: A Status Report
11:00	Hypertrophic Obstructive		Saibal Kar, MD
	Cardiomyopathy: Drugs, Surgery	4:20	Diabetic Cardiomyopathy:
	and Septal Ablation		An Update
	Barry J. Maron, MD		Clyde W. Yancy, MD
11:20	Diastolic Heart Failure:	4:40	Peripartum Cardiomyopathy in
	Management Strategies		the US: Clinical Profile,
44 - 40	Uri Elkayam, MD		Management and Risk of
11:40	Luncheon & Exhibits		Subsequent Pregnancy

Program Faculty

GUEST FACULTY

ANDREW J. BOYLE, MD

Uri Elkayam, MD

Medical Director, Heart Failure and Cardiac Transplantation Aurora St. Luke's Medical Center Aurora Cardiovascular Services Aurora Medical Group Milwaukee. Wisconsin

ANDREW J. BURGER. MD

Associate Director, Division of Cardiovascular Diseases Director of Cardiology Fellowship Program, University of Cincinnati Medical Center Professor of Clinical Medicine. College of Medicine. University of Cincinnati Cincinnati, Ohio

RICHARD N. CHANNICK, MD

Director, Pulmonary Hypertension Program Editor-in-Chief, Advances in Pulmonary Hypertension Massachusetts General Hospital Boston, Massachusetts

SAIBAL KAR, MD

Director, Interventional Cardiac Research, Cedars Sinai Medical Center Assistant Professor of Medicine, David Geffen School of Medicine, UCLA Los Angeles, California

ALAN MAISEL. MD

Professor of Medicine University of California, San Diego Director, CCU and Heart Failure Service, San Diego Veterans Affairs Medical Center San Diego, California

RAJ MAKKAR. MD

Director, Interventional Cardiology Associate Director, Cedars-Sinai Heart Institute, Cedars-Sinai Medical Center Associate Professor of Medicine, David Geffen School of Medicine, UCLA Los Angeles, California

BARRY J. MARON, MD

Director of the Hypertrophic Cardiomyopathy Center Minneapolis Heart Institute Foundation Minneapolis, Minnesota

ERNST R. von SCHWARZ, MD. PhD

Professor of Medicine. Cedars-Sinai Medical Center Director, Multidisciplinary Heart Failure Research Cedars-Sinai Heart Institute Professor of Medicine, David Geffen School of Medicine, UCLA Los Angeles, California

JONATHAN S. STEINBERG, MD

Chief, Division of Cardiology

Endowed Director, Al-Sabah Arrhythmia Institute, St. Luke's-Roosevelt Hospital Professor of Medicine, Columbia University, College of Physicians and Surgeons New York, New York

CLYDE W. YANCY, MD

Medical Director, Baylor Heart and Vascular Institute Chief of Cardiothoracic Transplantation Baylor University Medical Center President, American Heart Association, 2009-2010 Dallas, Texas

Program Faculty

USC FACULTY AT THE KECK SCHOOL OF MEDICINE

URI ELKAYAM. MD - Course Director

Chair, Heart Failure Team LAC+USC Medical Center Professor of Medicine Division of Cardiovascular Medicine

MICHAEL E. BOWDISH. MD

Director, Mechanical Circulatory Support Assistant Professor of Surgery Cardiovascular Thoracic Institute

VITO M. CAMPESE, MD

Chief, Division of Nephrology and Hypertension Professor of Medicine

DAVID CESARIO, MD. PhD

Director of Cardiac Electrophysiology Associate Professor of Clinical Medicine Division of Cardiovascular Medicine

PAMELYN CLOSE, MD MPH

Associate Professor of Clinical Medicine and Pediatrics Director, Adult and Pediatric Palliative Care LAC+USC Medical Center

TIEN M.H. NG. PharmD

Associate Professor of Clinical Pharmacy USC School of Pharmacy

DOUGLAS L. PRISCO. MD

Director of Sleep Medicine Assistant Professor of Clinical Medicine Division of Pulmonary, Critical Care and Sleep Medicine

Faculty Disclosure

Current guidelines state that participants in continuing medical education activities should be aware of any affiliation or financial interest that could affect the speaker's presentation(s). The Accreditation Council for Continuing Medical Education policy mandates that the provider adequately manages all identified potential conflicts of interest prior to the program. Faculty members have completed disclosure forms and potential conflicts of interest have been reviewed and resolved prior to the program. All disclosures will be listed in the course syllabus.

Cultural and Linguistic Competency - California AB 1195

This activity is in compliance with California Assembly Bill 1195, which requires that all CME activities address cultural and linguistic competency in patient care delivery to meet the concerns of a diverse population through effective and appropriate professional development.

Registration Information

COURSE LOCATION:

Millennium Biltmore Hotel 506 South Grand Avenue Los Angeles, CA 90071 (213) 624-1011

Special Group Rate Available:

A block of quest rooms are available for a rate of \$150 Single/Double plus tax. A block of rooms will be held for USC Heart Failure attendees until the block is filled. Reservations must be guaranteed by a major credit card. Cancellations without penalty must be made 36 hours prior to your arrival. Valet parking is available for overnight guests at a rate of \$40 and overnight self-parking at Pershing Square Is \$15.40. Overnight parking cannot be validated. Call the hotel directly to book your room!

TUITION:

\$125.00 Pre-payment required \$140.00 On-Site Registration and Payments Cost includes continental breakfast, lunch, course materials and self-parking. Confirmation and directions will be sent by e-mail. Pre-registration with payment required to secure lower tuition rate.

REGISTRATION LOCATION:

Registration begins at 7:00 a.m. in the Upper Galeria.

PARKING:

Parking will be validated for those commuters who park in the **Pershing Square Lot**. There will be a fee for valet or overnight parking.



If you have a disability, advance notification of any special needs by January 21, 2011 will help us better serve you.

If you register within 3 weeks of the course, please check with the Office of Continuing Medical Education at (323) 442-2555 or (800) USC -1119 for space availability and program changes before making travel arrangements. USC will not refund travel costs for cancelled courses. Fax us at (323) 442-2152 or (888) 665-86<mark>5</mark>0 toll free. Feel fr<mark>ee</mark> to c<mark>onta</mark>ct us via e-<mark>ma</mark>il at **usccme@usc.edu** or visit our web<mark>si</mark>te at www.usc.edu/cme.

PROGRAM APPLICATION FOR #2616 HEART FAILURE 2011

Saturday, January 29, 2011 Tuition: \$125.00 Pre-Payment Required; \$140 On-site

NAME			Degree			
Last	First					
MED. LIC#						
TELEPHONE ()						
ADDRESS Street or P.O. Box						
CITY	STATE	ZIP	+4			
SPECIALTY	E-MAIL					
Method of Payment: □ Check (payable to USC) □ Credit Card (Visa/MasterCard Only) Card#						
Authorized Signer		Amount \$				

Please mail check for \$125 made payable to the *University of Southern California* and this application to the Office of Continuing Medical Education, Keck School of Medicine of USC, 1975 Zonal Avenue, KAM 317. Los Angeles, CA 90033-1039. Call (800) USC-1119 or Fax (888) 665-8650. All on-site payments will be at the \$140 rate.

To register on-line, go to www.peopleware.net/0128 and choose course #2616. E-mail usccme@usc.edu or visit our web site at www.usc.edu/cme. Courses are subject to cancellation. Please check with the Office of Continuing Medical Education for availability if you register within 3 weeks prior to the starting date. USC will not refund travel costs for cancelled courses.